If you invested $10,000 in Australia's best-performing stock a year ago would have turned that into a $46,400 bonanza. Here's ...
Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...
Brookline Capital Markets initiated coverage of Medicus Pharma (MDCX) with a buy rating, citing the potential of its basal ...
10d
Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...
Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing ...
Sun Pharma is currently priced at Rs 1812.10, indicating a drop of 0.62% for today. The three-day simple moving average (SMA3) is Rs 1802.10. Sun Pharma has recently dropped below its 20-day ...
Democratic Sens. Elizabeth Warren (Mass.) and Tina Smith (Minn.) are reintroducing legislation aimed at strengthening U.S. pharmaceutical supply chains, warning the U.S. is overly relying on other ...
A long build-up is seen in the Torrent Pharma Futures, where we have seen an 18 per cent rise in the open interest with prices rising by 2.5 per cent. The stock price has broken out on the daily chart ...
A class action has been filed against Johnson & Johnson accusing it of selling medicines known to be ineffective. If the action is successful, anyone who bought the products in question since 2005 ...
In Brazil, researchers have identified substances with analgesic, anti-inflammatory, anti-hyperalgesic (against persistent pain) and anti-arthritic activity in the leaves of Annona squamosa, a ...
Swiss pharma giant Novartis (NOVN: VX) is to shut two sites belonging to its MorphoSys unit. The facilities in Munich, Germany, and Boston, USA, will close by end of 2025, Novartis confirmed after the ...
Denmark’s Zealand Pharma (Nasdaq: ZEAL) has been hit with a complete response letter (CRL) from the US regulator for glepaglutide, a long-acting GLP-2 analog. The therapy, which is being developed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback